Presentations will feature insights into optimizing VP1 ratios and the development of a high-yielding scalable Sf9-baculovirus platform for AAV production. Lexeo is developing therapies targeting ...

VectorY Therapeutics (VectorY), a biotechnology company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced that it will have four feat ...

“We are particularly proud of our exciting preclinical data in amyotrophic lateral sclerosis (ALS), Huntington’s disease, and of our optimized AAV & baculovirus production process for one-time ...

Research highlights AAV manufacturing optimization via Lexeo’s Sf9-baculovirus processNEW YORK, May 01, 2025 (GLOBE NEWSWIRE) ...

Stats: 11 goals, 21 assists, minus-7 rating in 76 games. Contract: $5.1 million AAV through 2027-28. The buzz: There's been repeated emphasis since the coaching change for Compher to use his ...

--(BUSINESS WIRE)--Affinia Therapeutics (“Affinia”), an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies for ...